Scholars Central

Conference abstractPublished 17 Oct 2016

A multi-targeted approach for treating pancreatic cancer

Authors: Chrystal U Louis, Birgit Schoeberl

Merrimack Pharmaceuticals, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pancreatic cancer often presents as inoperable, locally-advanced or metastatic disease. With traditional forms of chemotherapy, longterm survival for patients with metastatic disease is less than 5%. Due to the heterogeneity within pancreatic lesions, investigators are beginning to tailor treatment regimens to the pathology and biology of individual tumors. Using a systems engineering approach, we have developed both targeted and untargeted nanoliposomal molecules as well as signaling inhibitors to combat malignant solid tumors like pancreatic cancer. Nal-IRI (liposomal irinotecan, ONIVYDEÃ?®), MM-310 (EphA2-targeted docetaxel nanoliposome), and istiratumab (a tetravalent IGF-1R and ErbB3 inhibitor) are three examples of novel therapeutic candidates designed to utilize the tumor biology and microenvironment to improve anti-tumor efficacy. Nal-IRI takes advantage of both leaky vasculature and tumor associated macrophages within the tumor environment to enhance delivery and activity of SN-38. With an EphA2-targeting arm, MM-310 is a next generation nanoliposome providing enhanced delivery of and specificity docetaxel to EphA2-positive malignancies. Lastly, istiratumab inhibits pro-survival signaling through the PI3K/AKT/mTOR pathway by blocking and subsequently stripping IGF-1R and ErbB3 from the surface of tumor cells. Nal-IRI is currently being investigated in combination with 5FU, leucovorin, and oxaliplatin in patients with newly diagnosed metastatic pancreatic cancer. Targeted ()biomarker-driven patient selection is being utilized in both the phase 1 study of MM-310 for patients with EphA2-positive cancers, and in the phase 2 study of istiratumab in combination with nab-paclitaxel and gemcitabine in newly diagnosed metastatic pancreatic cancer patients who have elevated levels of free IGF-1 in their serum.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pancreatic Disorders & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPancreatic Disorders & Therapy
  • SubjectGastroenterology & Hepatology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Chrystal U Louis”
  • BylineArticles whose byline prints “Birgit Schoeberl”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels